Research Examines Combination Treatment for Hepatitis C

1. Research Examines
Combination Treatment
for Hepatitis C

2. Research
Examines
Combination
Treatment for
Hepatitis C
A paper co-written by Robert Hindes, MD, interprets the results of a phase 2
randomized, open label trial of the nucleoside polymerase inhibitor
sofosbuvir used in combination with ribavirin and pegylated interferon alfa2a to treat genotype 1 hepatitis C infection. In addition to the efficacy of the
above-outlined therapy, the researchers looked closely at its safety. Robert
Hindes, MD, and his peers analyzed data originating from more than 40
centers in the United States and Puerto Rico between March and September
2011. To enroll in the study, patients had to be older than 18 and exhibit
chronic and untreated HCV infection.

3. Research
Examines
Combination
Treatment for
Hepatitis C
The researchers divided the patients into three cohorts, with each receiving
a different treatment regimen. Overall, the data indicates that patients
tolerate sofosbuvir well over the 12-week treatment period. Further, the
study concludes that trials ought to move forward examining sofosbuvir
therapy in people with HCV and cirrhosis.

4. Research
Examines
Combination
Treatment for
Hepatitis C
Recently, the U.S. Food and Drug Administration approved sofosbuvir for
use in treating patients with hepatitis C.